Alex Therapeutics and Navamedic Partner For Companion App for Parkinson’s Treatment
The app will work alongside prescription drug treatment Flexilev.
Stock.adobe.com
More and more, pharmaceutical companies are turning to smart phones to enhance treatments.
Alex Therapeutics announced that it has partnered with Navamedic to develop an app to be used alongside prescription Parkinson’s disease treatment Flexilev.1 According to a press release, the app will provide users with medication management support and will be designed specifically for people living with Parkinson’s disease.
Parkinson’s impacts both motor functions and cognitive ability. The app will provide patients struggling with these impacts of the disease with features such as reminders and treatment logs.
Alex Therapeutics will combine its digital health expertise with Navamedic’s drug knowledge.
In a press release, Alex Therapeutics founder and CEO John Drakenberg said, "We are proud to partner with Navamedic to bring this tailored solution to the Parkinson's community. Our goal is to empower patients to manage their treatments effectively, for better symptom relief and improved quality of life."
Kathrine Gamborg Andreassen, CEO of Navamedic, added, “We are excited to collaborate with Alex Therapeutics to enhance the lives of Parkinson's patients through the companion app. This partnership not only reflects our commitment to making the treatment more accessible and manageable, but also underscores our dedication to easing the burden that patients face in their day-to-day care."
This is Alex Therapeutics’ latest collaboration. In January of this year, the company partnered with Vicore Pharma to develop a mobile app designed to provide treatment for anxiety based on cognitive behavioral therapy.2
In a press release issued at the time, Drakenberg said, “It's very rewarding to see that our tailored, evidence-based CBT intervention in Almee had a clinically meaningful impact for PF patients suffering from anxiety. The results of the COMPANION study demonstrate what can be achieved through a great partnership like the one we've had with Vicore Pharma. It's really groundbreaking, with so few digital therapies having published such positive randomized controlled trial results to date. We've shown how partnering to design and develop engaging, user-friendly, patient-facing apps is the best way to work together to change behavior and improve patient outcomes.”
In the same press release, Vicore’s CEO Ahmed Mousa added, “We're so pleased to see these positive results in the COMPANION pivotal study and believe that Almee can play a key role in combination with molecular therapies to address individuals suffering from pulmonary fibrosis in a holistic way."
Dr. Maureen Horton, professor of pulmonary and critical care medicine at Johns Hopkins University School of Medicine (retired) and principal investigator on the COMPANION study, also said, “It is very encouraging to see a digital CBT demonstrating a clear clinical benefit for individuals suffering from the mental health burden that accompanies pulmonary fibrosis. Providing behavior-modifying tools that enhance quality of life represents a new addition to a comprehensive treatment approach for patients suffering from this devastating disease."
Source
- Alex Therapeutics Has Signed an Exclusive Agreement with Navamedic for the Development of a Companion App to Aid in the Treatment of Parkinson’s Disease. Alex Therapeutics. September 12, 2024. https://www.prnewswire.com/news-releases/alex-therapeutics-has-signed-an-exclusive-agreement-with-navamedic-for-the-development-of-a-companion-app-to-aid-in-the-treatment-of-parkinsons-disease-302246418.html
- Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety. Alex Therapeutics. January 4, 2024. Accessed September 12, 2024. https://www.prnewswire.com/news-releases/alex-therapeutics-reports-positive-results-from-the-randomized-controlled-trial-of-its-digital-therapy-for-anxiety-302026100.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
